PL1871380T3 - Zastosowanie kombinacji związku prostaglandyny i inhibitora pompy protonowej w leczeniu zaburzeń żołądkowo-jelitowych - Google Patents

Zastosowanie kombinacji związku prostaglandyny i inhibitora pompy protonowej w leczeniu zaburzeń żołądkowo-jelitowych

Info

Publication number
PL1871380T3
PL1871380T3 PL06731937T PL06731937T PL1871380T3 PL 1871380 T3 PL1871380 T3 PL 1871380T3 PL 06731937 T PL06731937 T PL 06731937T PL 06731937 T PL06731937 T PL 06731937T PL 1871380 T3 PL1871380 T3 PL 1871380T3
Authority
PL
Poland
Prior art keywords
treatment
combined use
proton pump
gastrointestinal disorders
pump inhibitor
Prior art date
Application number
PL06731937T
Other languages
English (en)
Polish (pl)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of PL1871380T3 publication Critical patent/PL1871380T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06731937T 2005-04-12 2006-04-11 Zastosowanie kombinacji związku prostaglandyny i inhibitora pompy protonowej w leczeniu zaburzeń żołądkowo-jelitowych PL1871380T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67023805P 2005-04-12 2005-04-12
PCT/JP2006/308001 WO2006109881A1 (en) 2005-04-12 2006-04-11 Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
EP06731937A EP1871380B1 (en) 2005-04-12 2006-04-11 Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders

Publications (1)

Publication Number Publication Date
PL1871380T3 true PL1871380T3 (pl) 2012-03-30

Family

ID=36685683

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06731937T PL1871380T3 (pl) 2005-04-12 2006-04-11 Zastosowanie kombinacji związku prostaglandyny i inhibitora pompy protonowej w leczeniu zaburzeń żołądkowo-jelitowych

Country Status (18)

Country Link
US (1) US8962688B2 (https=)
EP (1) EP1871380B1 (https=)
JP (2) JP5711442B2 (https=)
KR (2) KR20140069182A (https=)
CN (1) CN101198334B (https=)
AU (1) AU2006234632B2 (https=)
BR (1) BRPI0610557A2 (https=)
CA (1) CA2602812C (https=)
DK (1) DK1871380T3 (https=)
ES (1) ES2371658T3 (https=)
IL (1) IL186374A (https=)
NO (1) NO20075764L (https=)
NZ (1) NZ562763A (https=)
PL (1) PL1871380T3 (https=)
PT (1) PT1871380E (https=)
RU (1) RU2468800C2 (https=)
WO (1) WO2006109881A1 (https=)
ZA (1) ZA200709072B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ539582A (en) * 2002-10-23 2007-07-27 Sucampo Ag Prostaglandin compounds for the treatment of obesity
JP5427029B2 (ja) * 2006-09-06 2014-02-26 スキャンポ・アーゲー 消化管の重炭酸分泌を促進するための方法および組成物
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
WO2009157397A1 (ja) * 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
US20120270945A1 (en) * 2011-04-19 2012-10-25 Sucampo Ag Method for modulating cytokine activity
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR20160015100A (ko) 2014-07-30 2016-02-12 미래파인켐 주식회사 프로스타글란딘 중간체의 제조방법
KR20170025682A (ko) 2015-08-31 2017-03-08 미래파인켐 주식회사 프로스타글란딘 유도체의 신규한 제조방법
CN107582556A (zh) * 2017-09-15 2018-01-16 成都泠汐尚品科技有限公司 一种治疗消化性溃疡的药物复方制剂
CN108051553A (zh) * 2017-12-29 2018-05-18 武汉轻工大学 一种仔猪肠道功能保护剂的筛选方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225439A (en) * 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5428062A (en) * 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
JPH0688966B2 (ja) * 1987-01-28 1994-11-09 株式会社アールテック・ウエノ プロスタグランジンｅ類およびそれを含む抗潰瘍剤
US5221763A (en) * 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
TW224942B (https=) * 1990-04-04 1994-06-11 Adka Ueno Kk
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
WO1997047595A1 (en) * 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
SE9804314D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New pharmaceutical formulation
BRPI0014869B8 (pt) * 1999-10-15 2021-05-25 Sucampo Ag prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
EP1267883B1 (en) * 2000-04-06 2009-06-17 Sucampo AG Bile secretion promoting composition for liver transplantation containing a 15-keto-prostaglandin
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
EP1575596B1 (en) * 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia
WO2004064719A2 (en) * 2003-01-24 2004-08-05 State Of Israel, Ministry Of Agriculture Synergistic compositions and methods for potentiating anti-oxidative activity
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid

Also Published As

Publication number Publication date
KR20140069182A (ko) 2014-06-09
ZA200709072B (en) 2008-11-26
DK1871380T3 (da) 2011-11-21
ES2371658T3 (es) 2012-01-05
IL186374A0 (en) 2008-03-20
CA2602812A1 (en) 2006-10-19
WO2006109881A1 (en) 2006-10-19
PT1871380E (pt) 2011-11-21
RU2468800C2 (ru) 2012-12-10
KR101466980B1 (ko) 2014-12-01
IL186374A (en) 2013-05-30
JP5711442B2 (ja) 2015-04-30
EP1871380B1 (en) 2011-10-19
RU2007141655A (ru) 2009-05-20
AU2006234632A1 (en) 2006-10-19
AU2006234632B2 (en) 2011-10-27
BRPI0610557A2 (pt) 2010-06-29
US8962688B2 (en) 2015-02-24
NO20075764L (no) 2008-01-14
JP2008535774A (ja) 2008-09-04
CA2602812C (en) 2014-11-18
NZ562763A (en) 2010-12-24
EP1871380A1 (en) 2008-01-02
KR20070119753A (ko) 2007-12-20
CN101198334A (zh) 2008-06-11
JP2013121972A (ja) 2013-06-20
US20070276006A1 (en) 2007-11-29
CN101198334B (zh) 2013-02-06

Similar Documents

Publication Publication Date Title
ZA200709072B (en) Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
AP2870A (en) Odcase inhibitors for the treatment of malaria
IL192691A0 (en) Hydantoin compounds for the treatment of inflammatory disorders
ZA200700384B (en) Hydantoin derivatives for the treatment of inflammatory disorders
ZA200806074B (en) Compounds for the treatment of inflammatory disorders
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL181238A0 (en) Therapeutic uses of inhibitors of rtp801
IL190920A0 (en) Compounds for the treatment of metabolic disorders
PL1685834T3 (pl) Zastosowanie kwasu pinolenowego do leczenia otyłości
IL191750A0 (en) Imidazole derivatives for the treatment of gastrointestinal disorders
IL181332A (en) A long-term treatment of human gastrointestinal disorders containing prostaglandin compound
SI1912640T1 (sl) Uporaba inhibitorja hdac panobinostata za zdravljenje mieloma
SI2366393T1 (sl) Roflumilast za zdravljenje pljučne hipertenzije
IL186286A0 (en) Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
IL178907A0 (en) Use of sulglicotide for the treatment of mucositis
WO2006042277A3 (en) Extended release compositions of proton pump inhibitors
IL179092A0 (en) Spiroderivatives for the treatment of hypertension
HK1137934A (en) Use of hdac inhibitors for the treatment of melanoma
GB0406017D0 (en) The treatment of inflammatory disorders
GB0406016D0 (en) The treatment of inflammatory disorders
HK1119685A (en) Compounds for the treatment of inflammatory disorders
GB2445888B (en) Treatment of hypertension
IL165438A0 (en) Use of amide derivative of ge2270 factor a3 for the treatment of acne
ZA200906906B (en) Use of HDAC inhibitors for the treatment of melanoma
IL201439A0 (en) Use of hdac inhibitors for the treatment of melanoma